Ketamine: A Neglected Therapy for Alzheimer Disease.
作者信息
Smalheiser Neil R
机构信息
Department of Psychiatry, Psychiatric Institute, University of Illinois School of Medicine, Chicago, IL, United States.
出版信息
Front Aging Neurosci. 2019 Jul 24;11:186. doi: 10.3389/fnagi.2019.00186. eCollection 2019.
Abstract
摘要
相似文献
1
Ketamine: A Neglected Therapy for Alzheimer Disease.
Front Aging Neurosci. 2019 Jul 24;11:186. doi: 10.3389/fnagi.2019.00186. eCollection 2019.
2
Repurposing strategies for tropical disease drug discovery.
Bioorg Med Chem Lett. 2016 Jun 1;26(11):2569-76. doi: 10.1016/j.bmcl.2016.03.103. Epub 2016 Mar 30.
3
Revisiting Repurposing.
Assay Drug Dev Technol. 2016 Dec;14(10):554-556. doi: 10.1089/adt.2016.766.
4
High Throughput and Computational Repurposing for Neglected Diseases.
Pharm Res. 2018 Dec 17;36(2):27. doi: 10.1007/s11095-018-2558-3.
5
Modern Approaches for the Discovery of Anti-Infectious Drugs for the Treatment of Neglected Diseases.
Curr Top Med Chem. 2018;18(5):369-381. doi: 10.2174/1568026618666180509151146.
6
Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases.
ChemMedChem. 2017 Aug 22;12(16):1235-1253. doi: 10.1002/cmdc.201700259. Epub 2017 Jul 11.
7
In silico repositioning of approved drugs for rare and neglected diseases.
Drug Discov Today. 2011 Apr;16(7-8):298-310. doi: 10.1016/j.drudis.2011.02.016. Epub 2011 Mar 1.
8
Repurposing for neglected diseases.
Science. 2009 Nov 13;326(5955):935; author reply 935. doi: 10.1126/science.326.5955.935-a.
9
Ketamine: repurposing and redefining a multifaceted drug.
Drug Discov Today. 2014 Dec;19(12):1848-54. doi: 10.1016/j.drudis.2014.08.017. Epub 2014 Sep 16.
10
Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing.
JCO Clin Cancer Inform. 2019 May;3:1-9. doi: 10.1200/CCI.19.00001.
引用本文的文献
1
Exploring the Neuroprotective and Neuropsychiatric Symptom Management Potential of Ketamine in Alzheimer's Disease.
Cureus. 2025 Jun 27;17(6):e86855. doi: 10.7759/cureus.86855. eCollection 2025 Jun.
2
Combinatorial targeting of NMDARs and 5-HTRs exerts beneficial effects in a mouse model of Alzheimer's disease.
Alzheimers Res Ther. 2025 Jul 15;17(1):160. doi: 10.1186/s13195-025-01804-9.
3
Ketamine does not rescue plaque load or gap detection in the 5XFAD mouse model of Alzheimer's disease.
Front Aging Neurosci. 2025 Feb 3;17:1505908. doi: 10.3389/fnagi.2025.1505908. eCollection 2025.
4
Increased GABBR2 Expression on Cell Membranes Causes Increased Ca2 + Inward Flow, Associated with Cognitive Impairment in Early Alzheimer's Disease.
Biochem Genet. 2024 Dec 26. doi: 10.1007/s10528-024-11004-z.
5
Therapeutic Potential of Intravenous Ketamine in Early-Onset Dementia: A Case Report.
Cureus. 2024 Jul 24;16(7):e65261. doi: 10.7759/cureus.65261. eCollection 2024 Jul.
6
Early Astrocytic Dysfunction Is Associated with Mistuned Synapses as well as Anxiety and Depressive-Like Behavior in the AppNL-F Mouse Model of Alzheimer's Disease.
J Alzheimers Dis. 2024;100(3):1017-1037. doi: 10.3233/JAD-231461.
7
Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats.
Cells. 2024 Apr 12;13(8):669. doi: 10.3390/cells13080669.
8
Pathogenesis of Depression in Alzheimer's Disease.
Neurochem Res. 2024 Mar;49(3):548-556. doi: 10.1007/s11064-023-04061-0. Epub 2023 Nov 28.
9
A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression.
Int J Mol Sci. 2023 Aug 7;24(15):12513. doi: 10.3390/ijms241512513.
10
Ketamine exerts dual effects on the apoptosis of primary cultured hippocampal neurons from fetal rats in vitro.
Metab Brain Dis. 2023 Oct;38(7):2417-2426. doi: 10.1007/s11011-023-01236-0. Epub 2023 Jun 5.
本文引用的文献
1
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.
Pharmacol Biochem Behav. 2019 Jun;181:53-59. doi: 10.1016/j.pbb.2019.04.008. Epub 2019 Apr 26.
2
(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
Br J Pharmacol. 2019 Jul;176(14):2573-2592. doi: 10.1111/bph.14683. Epub 2019 May 13.
3
Memantine for dementia.
Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi: 10.1002/14651858.CD003154.pub6.
4
()-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions.
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13.
5
Antidepressant-relevant concentrations of the ketamine metabolite (2,6)-hydroxynorketamine do not block NMDA receptor function.
Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169. doi: 10.1073/pnas.1816071116. Epub 2019 Feb 22.
6
Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline.
Neurobiol Aging. 2019 Apr;76:125-132. doi: 10.1016/j.neurobiolaging.2018.12.019. Epub 2019 Jan 7.
7
Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2,6)-hydroxynorketamine.
Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):297-302. doi: 10.1073/pnas.1814709116. Epub 2018 Dec 17.
8
AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine.
Biol Psychiatry. 2018 Oct 15;84(8):591-600. doi: 10.1016/j.biopsych.2018.05.007. Epub 2018 May 14.
9
NMDAR-independent, cAMP-dependent antidepressant actions of ketamine.
Mol Psychiatry. 2019 Dec;24(12):1833-1843. doi: 10.1038/s41380-018-0083-8. Epub 2018 Jun 12.
10
Memantine ameliorates depressive-like behaviors by regulating hippocampal cell proliferation and neuroprotection in olfactory bulbectomized mice.
Neuropharmacology. 2018 Jul 15;137:141-155. doi: 10.1016/j.neuropharm.2018.04.013. Epub 2018 May 4.
Zotero 插件